Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

444 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Upadacitinib Reduces Crohn's Disease Symptoms Within the First Week of Induction Therapy.
Colombel JF, Hisamatsu T, Atreya R, Bresso F, Thin L, Panaccione R, Parra RS, Ford S, Remple VP, Lacerda AP, Anyanwu SI, Mallick M, Garrison A, Regueiro M. Colombel JF, et al. Among authors: panaccione r. Clin Gastroenterol Hepatol. 2024 Aug;22(8):1668-1677. doi: 10.1016/j.cgh.2024.02.027. Epub 2024 Mar 15. Clin Gastroenterol Hepatol. 2024. PMID: 38492903 Free article. Clinical Trial.
Upadacitinib Achieves Clinical and Endoscopic Outcomes in Crohn's Disease Regardless of Prior Biologic Exposure.
Peyrin-Biroulet L, Panaccione R, Louis E, Atreya R, Rubin DT, Lindsay JO, Siffledeen J, Lukin DJ, Wright J, Watanabe K, Ford S, Remple VP, Lacerda AP, Dubcenco E, Garrison A, Zhou Q, Berg S, Anyanwu SI, Schreiber S. Peyrin-Biroulet L, et al. Among authors: panaccione r. Clin Gastroenterol Hepatol. 2024 Oct;22(10):2096-2106. doi: 10.1016/j.cgh.2024.02.026. Epub 2024 Mar 15. Clin Gastroenterol Hepatol. 2024. PMID: 38492904 Free article. Clinical Trial.
Risankizumab versus Ustekinumab for Moderate-to-Severe Crohn's Disease.
Peyrin-Biroulet L, Chapman JC, Colombel JF, Caprioli F, D'Haens G, Ferrante M, Schreiber S, Atreya R, Danese S, Lindsay JO, Bossuyt P, Siegmund B, Irving PM, Panaccione R, Cao Q, Neimark E, Wallace K, Anschutz T, Kligys K, Duan WR, Pivorunas V, Huang X, Berg S, Shu L, Dubinsky M; SEQUENCE Study Group. Peyrin-Biroulet L, et al. Among authors: panaccione r. N Engl J Med. 2024 Jul 18;391(3):213-223. doi: 10.1056/NEJMoa2314585. N Engl J Med. 2024. PMID: 39018531 Clinical Trial.
Risankizumab for Ulcerative Colitis: Two Randomized Clinical Trials.
Louis E, Schreiber S, Panaccione R, Bossuyt P, Biedermann L, Colombel JF, Parkes G, Peyrin-Biroulet L, D'Haens G, Hisamatsu T, Siegmund B, Wu K, Boland BS, Melmed GY, Armuzzi A, Levine P, Kalabic J, Chen S, Cheng L, Shu L, Duan WR, Pivorunas V, Sanchez Gonzalez Y, D'Cunha R, Neimark E, Wallace K, Atreya R, Ferrante M, Loftus EV Jr; INSPIRE and COMMAND Study Group. Louis E, et al. Among authors: panaccione r. JAMA. 2024 Sep 17;332(11):881-897. doi: 10.1001/jama.2024.12414. JAMA. 2024. PMID: 39037800 Clinical Trial.
Comparative Efficacy and Safety of Upadacitinib vs. Vedolizumab, Ustekinumab, and Tofacitinib After Induction and Maintenance for Ulcerative Colitis: Three Matching-Adjusted Indirect Comparisons.
Reinisch W, Melmed GY, Nakase H, Seidelin J, Ma C, Xuan S, Tran J, Remple V, Wegrzyn L, Levy G, Sanchez Gonzalez Y, Panaccione R. Reinisch W, et al. Among authors: panaccione r. Adv Ther. 2024 Oct;41(10):3832-3849. doi: 10.1007/s12325-024-02912-y. Epub 2024 Aug 10. Adv Ther. 2024. PMID: 39126596 Free PMC article.
Reliability of Intestinal Ultrasound for Evaluating Crohn's Disease Activity Using Point-of-care and Central Reading.
Goodsall TM, An YK, Andrews JM, Begun J, Friedman AB, Lee A, Lewindon PJ, Spizzo P, Rodgers N, Taylor KM, White LS, Wilkens R, Wright EK, Zou L, Maguire BR, Parker CE, Rémillard J, Novak KL, Panaccione R, Feagan BG, Jairath V, Ma C, Bryant RV. Goodsall TM, et al. Among authors: panaccione r. Clin Gastroenterol Hepatol. 2024 Aug 28:S1542-3565(24)00773-0. doi: 10.1016/j.cgh.2024.08.007. Online ahead of print. Clin Gastroenterol Hepatol. 2024. PMID: 39209200
Preliminary Results From a Multicenter, Randomized Trial Using Fecal Microbiota Transplantation to Induce Remission in Patients With Mild-to-Moderate Crohn's Disease.
Kao D, Wong K, Jijon H, Moayyedi P, Franz R, McDougall C, Hotte N, Panaccione R, Semlacher E, Kroeker KI, Peerani F, MacDonald KV, Xu H, Narula N, Turbide C, Marshall DA, Madsen KL. Kao D, et al. Among authors: panaccione r. Am J Gastroenterol. 2024 Nov 12. doi: 10.14309/ajg.0000000000003196. Online ahead of print. Am J Gastroenterol. 2024. PMID: 39530534
Patient and Health Care Professional Perceptions of the Experience and Impact of Symptoms of Moderate-to-Severe Crohn's Disease in US and Europe: Results from the Cross-Sectional CONFIDE Study.
Schreiber S, Hunter Gibble T, Panaccione R, Rubin DT, Travis S, Hibi T, Potts Bleakman A, Panni T, Favia AD, Kayhan C, Atkinson C, Saxena S, Dubinsky MC. Schreiber S, et al. Among authors: panaccione r. Dig Dis Sci. 2024 Jul;69(7):2333-2344. doi: 10.1007/s10620-024-08434-5. Epub 2024 May 3. Dig Dis Sci. 2024. PMID: 38700629 Free PMC article.
Associations of NOD2 polymorphisms with Erysipelotrichaceae in stool of in healthy first degree relatives of Crohn's disease subjects.
Turpin W, Bedrani L, Espin-Garcia O, Xu W, Silverberg MS, Smith MI, Garay JAR, Lee SH, Guttman DS, Griffiths A, Moayyedi P, Panaccione R, Huynh H, Steinhart HA, Aumais G, Dieleman LA, Turner D; CCC IBD GEM Project research team; Paterson AD, Croitoru K. Turpin W, et al. Among authors: panaccione r. BMC Med Genet. 2020 Oct 15;21(1):204. doi: 10.1186/s12881-020-01115-w. BMC Med Genet. 2020. PMID: 33059653 Free PMC article.
444 results